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Abstract
We aimed to characterize metabolites during tuberculosis (TB) disease and identify new pathophysiologic pathways
involved in infection as well as biomarkers of TB onset, progression and resolution. Such data may inform development of
new anti-tuberculosis drugs. Plasma samples from adults with newly diagnosed pulmonary TB disease and their matched,
asymptomatic, sputum culture-negative household contacts were analyzed using liquid chromatography high-resolution
mass spectrometry (LC-MS) to identify metabolites. Statistical and bioinformatics methods were used to select accurate
mass/charge (m/z) ions that were significantly different between the two groups at a false discovery rate (FDR) of q,0.05.
Two-way hierarchical cluster analysis (HCA) was used to identify clusters of ions contributing to separation of cases and
controls, and metabolomics databases were used to match these ions to known metabolites. Identity of specific D-series
resolvins, glutamate and Mycobacterium tuberculosis (Mtb)-derived trehalose-6-mycolate was confirmed using LC-MS/MS
analysis. Over 23,000 metabolites were detected in untargeted metabolomic analysis and 61 metabolites were significantly
different between the two groups. HCA revealed 8 metabolite clusters containing metabolites largely upregulated in
patients with TB disease, including anti-TB drugs, glutamate, choline derivatives, Mycobacterium tuberculosis-derived cell
wall glycolipids (trehalose-6-mycolate and phosphatidylinositol) and pro-resolving lipid mediators of inflammation, known
to stimulate resolution, efferocytosis and microbial killing. The resolvins were confirmed to be RvD1, aspirin-triggered RvD1,
and RvD2. This study shows that high-resolution metabolomic analysis can differentiate patients with active TB disease from
their asymptomatic household contacts. Specific metabolites upregulated in the plasma of patients with active TB disease,
including Mtb-derived glycolipids and resolvins, have potential as biomarkers and may reveal pathways involved in TB
disease pathogenesis and resolution.
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Introduction
The global burden of tuberculosis (TB) is vast, with an estimated
8.6 million new TB cases and 1.3 million deaths due to the disease
in 2012 [1,2]. Challenges in global TB control include human
immunodeficiency virus (HIV)/TB co-infection and lack of
effective vaccines and point of care diagnostics [3]. Also, there
are no well-validated or specific biomarkers that can predict
transition from latent TB to active TB disease or are useful to
monitor efficacy of anti-TB drugs [4,5]. Additionally, the rising
global presence of multidrug resistant TB (MDR-TB) strains of
Mycobacterium tuberculosis (Mtb) constitutes a public health crisis
[1–3].
Metabolomics analysis incorporates nuclear magnetic resonance
(NMR) spectroscopy-based or mass spectrometry (MS)-based
technologies to identify hundreds to thousands of small-molecule
metabolites in biofluids or tissues, coupled with biostatistics and
bioinformatics to identify potential regulated biomarkers and
metabolic pathways associated with disease [6–8]. Targeted or
untargeted NMR- or MS-based metabolomics methods have
recently been shown to distinguish the presence of specific
PLOS ONE | www.plosone.org 1 October 2014 | Volume 9 | Issue 10 | e108854infectious diseases, to predict therapeutic responses to anti-
microbial agents, and to explore host-pathogen metabolic
interactions, including in malaria [9,10], chronic Pseudomonas
aeruginosa pulmonary infection [11], HIV [12], and sepsis [13].
Targeted metabolomics methods have been used to characterize
specific metabolites and regulated metabolic pathways endogenous
to Mtb itself in cell culture studies [14–17] and Mtb metabolites
possibly involved in drug resistance [18]. Metabolomics approach-
es have identified metabolic profiles associated with Mtb disease in
animal models using NMR [19,20] and in human latent TB
infection or active TB disease using NMR-based analysis of serum
[21] or MS-based analysis of sputum [22] or serum [23,24].
We designed the current proof-of-principle study to determine
the potential utility of high-resolution metabolomics to distinguish
adults with newly diagnosed pulmonary TB compared to their
matched household contacts and to determine potential metabolic
features that may reflect host-Mtb metabolic interactions.
Materials and Methods
Ethics Statement
This study was approved by the Institutional Review Board of
Emory University (Atlanta, GA, USA) and the Georgian National
Center for Tuberculosis and Lung Disease (NCTBLD) Ethics
Committee (Tbilisi, Georgia). All subjects provided written
informed consent for participation in the study.
Study Participants
Study participants for this ancillary metabolomics study were
selected from a double blind, randomized, controlled, prospective
trial of high-dose cholecalciferol treatment of patients with
pulmonary TB disease (clinicaltrials.gov identifier
NCT00918086) [25]. Inclusion criteria for patients were age $
18 years, newly diagnosed TB as determined by a positive acid-fast
bacilli (AFB) sputum smear, and later confirmed by a positive
sputum culture for Mtb (performed at the Georgian National TB
Reference Laboratory [NRL]) [26], #7 days of treatment with
anti-TB drug therapy. Exclusion criteria included .7 days of anti-
TB therapy (life time), hypercalcemia, nephrolithiasis, hyperpara-
thyroidism, sarcoidosis, history of organ transplant, liver cirrhosis,
requirement of hemodialysis, cancer in past 5 years, seizures,
current pregnancy or lactation, serum creatinine .250 mmol/L,
corticosteroid use in the past 30 days, current use of cytotoxic or
immunosuppressive drugs, and current incarceration. Inclusion
criteria for household contacts (controls) included lack of
symptoms suggestive of TB disease or any other acute illness
and documented negative sputum smear and culture. We chose a
convenience sample of 17 TB subjects that had data available for
their matched household contact.
Sputum Culture, Drug Susceptibility Testing and
First-Line Anti-TB Drug Therapy
Two sputum specimens were obtained from each patient
subsequently confirmed to have active pulmonary TB disease.
Direct sputum smears with Ziehl-Neelsen staining were examined
by light microscopy. All sputum samples were sent to the NRL for
culture on Lo ¨wenstein-Jensen (LJ)-based solid media, using
standard methodologies as previously described [26,27]. Positive
cultures were confirmed to be Mtb complex using phenotypic tests
and the MTBDRplus assay, as outlined elsewhere [26]. First-line
anti-TB drugs (isoniazid, rifampicin, pyrazinamide and ethambu-
tol) were given to all TB disease subjects # one week prior to the
plasma sampling. Drug susceptibility testing (DST) was done using
absolute concentration method and for second-line drugs with
proportion method on solid media with standard methodology, as
previously described [27].
To compare individuals with TB disease to those without
evident TB disease, we also obtained blood from 17 asymptomatic
household contacts of all studied TB disease subjects who
accompanied the index TB patient to clinic on the baseline visit
(typically a close relative) and were documented to be sputum Mtb
culture negative. None of these individuals received anti-TB drugs.
Plasma Sample Collection
Peripheral blood samples were obtained by venipuncture from
all 17 subjects with TB disease and well as an asymptomatic
household contact without TB disease. Blood was collected in
ethylenediaminetetraacetic acid (EDTA)-containing tubes, centri-
fuged and isolated plasma immediately stored frozen at 280uC.
Samples were subsequently shipped on dry ice from Tbilisi to
Emory University, Atlanta, GA, USA. Samples were never
previously thawed, remained frozen during transit, and were
frozen at 280uC in Atlanta prior to metabolomics analysis.
Macronutrient Intake and Body Mass Index Assessment
Mean daily dietary intake of macronutrients (total calories,
protein, fat and carbohydrate) was estimated in the three days
prior to the blood collection using a validated culture-specific
nutrient intake assessment instrument using the Nutrition Data
System for Research software, version 2011, as previously
described [25,28]. Body mass index [BMI; body weight (kg)/
height (m
2)] was calculated at entry in all subjects using data
obtained from a calibrated research stadiometer and digital body
weight scale system (Tanita Inc; Arlington Heights, Illinois, USA).
Metabolomics Analysis
High-Resolution Metabolomics. Thawed plasma (65 mL)
was treated with 130 ml acetonitrile (2:1, v/v) containing an internal
isotopic standard mixture (3.5 mL/sample), as previously described
[29]. Briefly, the internal standard mix for quality control consisted
of 14 stable isotopic chemicals covering a broad range of chemical
properties represented in small molecules [29]. Samples were mixed
and placed in ice for 30 min prior to centrifugation for 10 min
(16,1006ga t4 uC) to removeprotein. The supernatants (10 mL),for
each high-resolution LC-MS analysis were then loaded onto an
autosampler maintained at 4uC and analyzed in triplicate using a
LTQ-Velos Orbitrap mass spectrometer (Thermo Scientific, San
Jose, CA, USA) and C18 chromatography (Higgins Analytical,
Targa, Mountain View, CA, USA, 2.1610 cm). Elution was
obtained with a formic acid/acetonitrile gradient [29] at a flow
rate of 0.35 ml/min for the initial 6 min and 0.5 ml/min for the
remaining 4 min. The first 2-min period consisted of 5% solution A
[2% (v/v) formic acid in water], 60% water, 35% acetonitrile,
followed by a 4-min linear gradient to 5% solution A, 0% water,
95% acetonitrile. The final 4-min period was maintained at 5%
solution A, 95% acetonitrile. The mass spectrometer was set to
collect data from mass/charge ratio (m/z) 85 to 2000 daltons over
the 10-minute chromatography period. Electrospray ionization was
used in positive ion mode for detection, as outlined [29,30].
Tandem Mass Spectrometry. Glutamate (m/z 148.0594)
and Mtb-derived trehalose-6-mycolate (m/z 801.5767) were
verified by tandem MS/MS and fragmentation of co-eluting
authentic reference standards added to plasma and prepared for
analysis as described previously [29,30]. Trehalose-6-mycolate for
verification studies was purified from a specific Mtb strain
(Colorado State University Mycobacteria Research Laboratory,
Fort Collins, CO). Identity of specific D-series resolvins [resolvin
D1 (RvD1), 7S, 8R,17S-trihydroxy-4Z, 9E, 11E, 13Z, 15E, 19Z-
Plasma Metabolomics in Human Pulmonary TB Disease
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trihydroxy-4Z, 8E, 10Z, 12E, 14E,19Z- docosahexaenoic acid)
and the aspirin-triggered RvD1 (AT-RvD1), 7S, 8R,17R-trihy-
droxy-4Z, 9E, 11E, 13Z, 15E, 19Z-docosahexaenoic acid] was
confirmed using lipid mediator metabololipidomics analytical
methods, as described by Serhan and colleagues [31,32]. Briefly,
five deuterium-labeled internal standards (0.5 ng) were added to
plasma aliquots [d5-RvD2, d8-5-hydroxyeicosatetraenoic acid (d8-
5-HETE), d4-leukotriene B4 (d4-LTB4), d5-lipoxin A4 (d5-LXA4)
and d4-prostaglandin E2 (d4-PGE2) to facilitate quantification of
mediator recovery. Samples were extracted using SPE columns,
eluted with methyl formate, and organic solvent evaporated using
a nitrogen stream. Samples were suspended in methanol for
analysis by liquid chromatography coupled with tandem mass
spectroscopy (LC-MS/MS), using QTrap ABI 5500 (ABSciex,
Framingham, MA) [31,33]. To monitor and quantify levels of the
SPMs derived from arachidonic acid, docosahexaenoic acid
(DHA) and eicosapentaenoic acid (EPA) in plasma samples
[34,35], multiple reaction monitoring (MRM) for signature ion
fragments was performed with identification accomplished using
LC retention time (RT) and $6 diagnostic ions of MS/MS
spectrum. Quantification was determined based on peak MRM
transition area and linear calibration curves [35].
Data Collection and Processing for High-Resolution
Metabolomics. LTQ-Velos Orbitrap MS data were continu-
ously collected over the 10-min chromatographic separation
period and stored as.Raw files. The.Raw files were converted
to.cdf format using Xcalibur file converter software (Thermo
Fisher, San Diego, CA) and used for data extraction. Peak
extraction and integration were performed using apLCMS with
xMSanalyzer 1.0 [8,36]. apLCMS (http://www.sph.emory.edu/
apLCMS) is an adaptive processing software package designed for
high resolution LC-MS data that performs data filtering, peak
detection, and alignment and generates a feature table, where a
feature is defined as the measured m/z, RT, and integrated ion
intensity. We define a metabolite as any chemical in a biological
system, where some metabolites may be gene-directed or
environmental chemicals [6]. xMSanalyzer enhances the feature
detection process by performing systematic data re-extraction and
combining results from different parameter settings ([36]; http://
sourceforge.net/projects/xmsanalyzer/).
Statistical Analysis
Descriptive statistics for demographic and clinical data were
performed. Two-tailed t-tests and two-tailed Fisher exact tests
were used to compare metabolomics results from patients with TB
disease and their household contacts using SAS version 9.3 (Cary,
NC, USA) for continuous and categorical data, respectively.
LIMMA, a package within the R framework for differential
expression analysis, was used to identify differentially expressed
metabolites between TB cases and household contacts [37]. To
account for multiple comparisons, P values were adjusted using
the Hochberg and Benjamini false discovery rate (FDR) at
q=0.05 to distinguish statistically significant metabolites that
differed between the two groups [38]. HCA was performed using
the differentially expressed metabolites to visualize patterns and
detect clusters of co-regulated metabolites by disease state [6,39].
An untargeted metabolome-wide association study (MWAS) based
on the Pearson correlation analysis of the differentially expressed
metabolites with all detected metabolites in plasma of subjects with
TB disease and HCA was performed to understand the global
association pattern of the discriminatory metabolites [6]. The
statistical significance of correlations was determined using the
Student’s t-test method and visualized using a Manhattan plot
where the x-axis corresponds to the metabolites (85–2000 m/z) and
the y-axis corresponds to the negative log10 of the p-value [40,41].
Targeted MWAS were also performed with m/z matching to the
anti-TB drugs rifampin and ethambutol differentially expressed in
TB disease versus HC subjects. FDR, HCA and Pearson
correlations analyses were performed using R [8,36]. Principal
component analysis was performed using the pcaMethods R
package (http://www.bioconductor.org/packages/release/bioc/
html/pcaMethods.html). Support vector machine analysis was
performed using the e1071 R package at default settings.
Metabolite Annotation and Pathway Analysis
Putative metabolite identification of the discriminatory ions
between TB and household contact subjects were determined
using the open-access Metlin metabolite database (http://metlin.
scripps.edu/) [42]. An in-house R package (manuscript in
preparation) incorporating a suite of major small molecule
databases [KEGG [43] http://www.genome.jp/kegg/), Human
Metabolome Database (HMDB) [44], MetaCyc (http://www.
metacyc.org), and ChemSpider (http://www.chemspider.com/)]
was used to enhance reliability of ion annotation matching high-
resolution m/z to metabolites in Metlin [45]. Pathway analysis was
performed using KEGG [43].
Results
Subject Characteristics
The mean age (35612 years) and sex of the 17 TB disease
subjects were similar to the 17 household contacts studied
(Table 1). All subjects were Caucasian; there were no differences
between the two groups in terms of annual income and maximum
educational level attained (not shown). The individuals with TB
disease consumed significantly greater total daily calories and
similar daily protein and fat intake per kg of body weight daily
compared to household contacts. Despite higher daily caloric
intake, the average body mass index (BMI) in the TB disease
cohort was significantly lower than in matched housemates,
reflecting the catabolic nature of TB disease [3,28].
High-Resolution Metabolomics Data
Extraction of mass spectral data derived from C18 chromatog-
raphy yielded 23,241 metabolites. Statistical analysis of the 34
subjects (FDR q=0.05) demonstrated 61 metabolites distinguishing
TB disease subjects from the household contacts. Figure 1A
depicts a Manhattan plot charting the –log P value for each
differentiating m/z. Table S1 in File S1 lists these significantly
different metabolites with m/z, respective RT, relative logintensities,
median coefficient of variation, and negative log P value.
Figure 1B shows box and whisker plots of log2 intensities for
six selected significant metabolites comparing the median and
interquartile range for metabolite intensities in the household
contacts (HC; left boxplot within each individual metabolite) and
TB disease subjects (right boxplot within each individual
metabolite). The individual m/z and putative metabolite identifi-
cations from Metlin are shown. The upper panel shows selected
metabolites that were increased in TB subjects: from left to right,
the amino acid glutamate, a D-series resolvin [31,33,34,46], and
the Mtb-specific cell wall glycolipid trehalose-6-mycolate [47,48],
respectively. The lower panel shows intensities of the metabolite
matching phosphatidylinositol (PI), a key phospholipid present the
cell wall of mycobacteria [47,48] that was increased in TB
subjects. This m/z matched to six putative PI molecules of different
carbon chain lengths. The lower panel also shows two unidentified
metabolites that were decreased in TB subjects relative to HC.
Plasma Metabolomics in Human Pulmonary TB Disease
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analysis of plasma metabolites differentiating individuals
with pulmonary TB disease from household contacts
Two-way hierarchical cluster analysis (HCA) of the 61
significant differentiating plasma metabolites is shown in Fig-
ure 2A. The pie chart (Figure 2B) depicts the distribution of the
61 differentiating metabolites within pan-metabolome categories
[6]. Of interest, the largest category (47%) of this classification did
not match to known metabolites in the Metlin metabolite
database. As an alternative approach, we also performed principal
component analysis (PCA; Figure S1) that showed a similar
metabolite separation pattern between TB disease subjects and
household contacts as seen with two-way hierarchical cluster
analysis (HCA) (Figure 1A). The model was evaluated using the
R2 and Q2 estimates (panel D). The model using the first two
Table 1. Demographic characteristics of individuals with TB disease and their asymptomatic household contacts.
Characteristic
a TB Disease (n=17) Household Contacts (n=17) P-value
Age [years; mean (SD)] 35 (12) 42 (11) 0.09
Male sex, n (%) 10 (59%) 6 (35%) 0.16
Current smoker, n (%) 13 (76%) 7 (41%) 0.036
Currently employed, n (%) 8 (47%) 11 (64%) 0.023
Total calorie intake [kcal/kg/day; mean (SD)] 56.6 (17.8) 42.1 (11.7) 0.009
Total protein intake [g/kg/day; mean (SD)] 1.7 (0.8) 1.2 (0.5) 0.058
Total fat intake [g/kg/day; mean (SD)] 2.0 (0.8) 1.5 (0.5) 0.07
Total carbohydrate intake [g/kg/day; mean (SD)] 8.3 (2.4) 5.5 (1.4) ,0.001
BMI [kg/m
2; mean (SD)] 20.7 (2.0) 25.6 (4.0) ,0.001
a Annual income and educational level were similar between the two groups (data not shown).
SD=standard deviation; BMI=body mass index; kcal/kg/day=kilocalories/kilogram/day; g/kg/day=gram/kilogram/day.
doi:10.1371/journal.pone.0108854.t001
Figure 1. Plasma metabolome-wide association study (MWAS) of pulmonary tuberculosis (TB) disease in adults. (A) The Manhattan
plot depicts the -log P analysis of 23,241 metabolites comparing 17 adults with newly diagnosed pulmonary TB disease and 17 asymptomatic adult
household contacts who were sputum smear and culture negative for Mtb. The x-axis represents the m/z of the metabolites, ordered in increasing
value from left (85) to right (2000). A total of 61 metabolites significantly differed [false discovery rate (FDR) q=0.05] between the two groups
(metabolites depicted above the horizontal dashed blue line). Metabolites above the horizontal dashed red line (n=122) distinguished the TB disease
and household contact cohorts at FDR q=0.10, while metabolites above the dashed green line (n=711) distinguished the two groups at FDR
q=0.20. (B) Box-and-whisker plots of log2 intensities comparing individuals with TB disease and household contacts for selected metabolites, with m/
z and putative metabolite identification from Metlin and KEGG (left to right upper panel: glutamate, D-series resolvin, and trehalose-6-mycolate,
respectively; left to right lower panel: phosphatidylinositol, and two unidentified metabolites that did not match to known metabolites in the
databases, respectively).
doi:10.1371/journal.pone.0108854.g001
Plasma Metabolomics in Human Pulmonary TB Disease
PLOS ONE | www.plosone.org 4 October 2014 | Volume 9 | Issue 10 | e108854principal components suggests good predictive ability (PC1:
R2=0.44, Q2=0.40; PC2: R2=0.7, Q2=0.64; PC3:
R2=0.74, Q2=0.60) [49].
Table S2 in File S1 lists the 59 metabolites with retention time
(RT) .30 seconds grouped according to HCA cluster, and
signifies cluster number, m/z, RT and putative metabolite match
from Metlin [42]. As shown in the HCA heat map (Figure 2A),
accurate mass metabolite matches within cluster 1 to 6 were all
significantly increased in subjects with TB disease. In contrast,
clusters 7 and 8 contained primarily unidentified (unmatched)
metabolites, most of which were decreased in subjects with TB
disease.
Metabolite cluster 5 contained m/z matches to the administered
anti-TB drugs rifampin and ethambutol (both the Na
+ and the H
+
adducts of these agents were detected). The m/z for the
administered anti-TB drugs isoniazid (m/z 120.0548) and pyrazin-
amide (m/z 124.0498) were detected at low intensity in some
individuals with TB disease. Targeted MWAS to determine the
association of m/z for rifampin and ethambutol with the full panel
of detected metabolites demonstrated that these were highly
correlated with the metabolites matching to isoniazid, pyrazin-
amide, and the isoniazid metabolites acetyl-hydrazine (m/z
97.0389) and isoniazid pyruvate (m/z 208.0682) [50,51] (not
shown). No anti-TB drug metabolite was detected in the
household contacts.
Verification studies for glutamate, D-series resolvins and
trehalose-6-mycolate
Tandem MS/MS and fragmentation of co-eluting authentic
reference standards added to plasma was used to verify glutamate,
D-series resolvins and trehalose 6-mycolate. One of the 61
significant plasma metabolites (m/z 399.2116) matched to several
possible D-series resolvins using the Metlin database. We refined
the annotation by using an in-house R package (manuscript in
preparation), which matched the resolvin m/z to two specific
resolvins, RvD1 and RvD2. As shown in Figure 3, verification
studies confirmed the positive identification of RvD1, RvD2, and
aspirin-triggered resolvin D1 (AT-RvD1) in the plasma from
subjects with TB disease [31,32]. Figure S2 shows the presence of
fragments 184.0736 and 86.0970 in both the reference standard
and plasma sample at the same retention time and indicates the
match to the [M-H2O+H] adduct for trehalose 6-mycolate is
correct.
Concomitant detection of putative Mtb cell wall-derived
metabolites and the D-series resolvin metabolite in
plasma of subjects with drug-susceptible or
drug-resistant TB disease
Co-detection of the m/z matched to trehalose-6-mycolate, PI,
and the D-series resolvins within study subject plasma (TB disease
subjects with drug-susceptible TB, MDR-TB, and household
contacts) is shown in Table 2. Notably, in all 13 patients with
drug-susceptible TB with the detectable trehalose-6-mycolate
metabolite in plasma, the PI metabolite was also concomitantly
detected. Also, in all 12 patients with drug-susceptible TB with
detectable plasma D-series resolvin(s) metabolite, both the
trehalose-6-mycolate and the PI metabolites were detected. One
of three patients with MDR-TB had concomitantly detectable D-
series resolvin(s) and the trehalose-6-mycolate and PI metabolites.
In another MDR-TB patient, the D-series resolvin(s) were
demonstrated, but neither of the two Mtb cell wall-related
metabolites was detected. The D-series resolvin(s), resolvin D1
and resolvin D2 were identified in the plasma of two household
contacts, but was not linked to detection of either of the putative
Mtb cell wall-related metabolites. One of the 17 household
contacts demonstrated the trehalose-6-mycolate metabolite and PI
concomitantly (Table 2).
Discussion
Our study demonstrates that discovery-based metabolomics
profiling method can differentiate adults with pulmonary TB
Figure 2. Significant metabolites that distinguish TB patients from household contacts. (A) Two-way hierarchical cluster analysis (HCA)
using C18 chromatography shows 8 clusters of metabolites from human plasma and illustrates the patterns distinguishing those with active TB from
household contacts without evidence of TB disease. The 17 subjects with TB disease (TB; shown in green) and the 17 household contacts (HC; shown
in red) are shown along the x-axis. (B) Pie chart depicts chemical classes of the 61 significant metabolites from panel 2A according to high-resolution
matches to metabolite databases [6].
doi:10.1371/journal.pone.0108854.g002
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guishing metabolite profile includes specific resolvins, glutamate,
and trehalose-6-mycolate, as well as other putative Mtb cell wall
metabolites. A unique feature of our study compared to previous
metabolomics studies in human TB is our use of liquid
chromatography high-resolution mass spectrometry (LC-MS)
metabolomics to profile .23,000 metabolites in plasma from
humans with TB disease and concomitantly, their asymptomatic
household contacts. Patients with active TB disease likely had
similar exposures (e.g. specific dietary foods, environmental
chemicals, household microbes, etc.) as the individual control
subjects living in the same dwelling. Thus, specific metabolite
differences between the two groups of subjects we report here were
not likely to be due to other differences in the ‘‘exposome’’ of the
respective groups [6] but rather were likely due to active Mtb
disease and drug treatment.
Among the differentiating metabolic features were two of the
four administered anti-TB drugs (rifampin and ethambutol). The
m/z for isoniazid and pyrazinamide were detected at low intensity
in some, but not all, individuals with TB disease. Metabolism and/
or excretion of these agents and/or the sensitivity of our LC-MS
method may explain why these latter drugs did not appear in the
distinguishing metabolite panel. However, targeted MWAS
showed the rifampin and ethambutol m/z were each highly
correlated with metabolites matching to isoniazid, pyrazinamide,
and the isoniazid metabolites acetyl-hydrazine and isoniazid
pyruvate.
We also identified several metabolites not previously shown in
plasma of patients with TB disease. Most notably, these included
endogenously produced lipid mediators involved in the resolution
of inflammation in a large number of conditions (specific D-series
resolvins) [34,35], and metabolites derived from the Mtb cell wall,
including the mycobacterium specific cell wall glycolipid trehalose-
6-mycolate and the non-specific cell wall phospholipid PI
[47,48,52,53]. In addition, many unidentified metabolites (un-
matched in Metlin) were either increased or decreased in the
plasma of the pulmonary TB disease subjects relative to controls,
and may represent future targets for investigation [6]. This large
proportion of unidentified metabolites is consistent with our
previous studies using an earlier adaptation of this LC-MS method
in several eukaryotic species, including man [7].
In our study, dietary intake does not seem to explain the overall
metabolite profile that discriminated the two groups. It is possible,
however, that the increased triglyceride metabolite (Table S2 in
File S1) was related to higher recent fat or carbohydrate intake
and the increased choline metabolite from increased intake of
choline-rich foods such as eggs and meats (not shown). It is highly
unlikely that modestly higher dietary protein intake in individuals
with TB disease relative to the household contacts (Table 1)
accounts for the single amino acid (glutamate) to be within the
discriminating metabolite profile.
There is considerable promise for metabolomic analyses to
advance understanding of TB and its pathogenesis. However,
some of the limited previous metabolomic studies in human TB
disease have lacked culture confirmation in all subjects, informa-
tion on the course of disease after TB samples were collected, or
dietary intake data [21–24]. Also, prior to the present study, the
analytic platforms used for metabolomic analysis in individuals
with TB disease measured a relatively small number of total
metabolites (total metabolites=30 to 498) [21–24]. Our similar
Figure 3. MS/MS fragmentation spectra show positive identification of resolvin D1 (RvD1), resolvin D2 (RvD2), and aspirin-
triggered resolvin D1 (AT-RvD1) in plasma from subjects with TB disease. Metabololipidomics analytical methods that incorporated high-
resolution liquid chromatography coupled with tandem mass spectroscopy (LC-MS/MS, ABI 5500, see methods) were used to verify these DHA-
derived specialized pro-resolving lipid mediators [31,33].
doi:10.1371/journal.pone.0108854.g003
Table 2. Linkage of trehalose-6-mycolate, phosphatidylinositol and the D-series resolvin metabolite(s) in plasma of patients
without or with MDR-TB.
Metabolite feature Non-MDR-TB patients
ab MDR-TB patients
c Household contacts
d
Trehalose-6-mycolate 13/14 1/3 1/17
Phosphatidylinositol (PI) 14/14 1/3 1/17
D-series resolvin 12/14 2/3 2/17
a In all 13 non-MDR-TB patients with detectable trehalose-6-mycolate metabolite in plasma, the phosphatidylinositol metabolite was also detected.
b In all 12 non-MDR-TB patients with the D-series resolvin(s) metabolite detected in plasma, the trehalose-6-mycolate and PI metabolites were concomitantly detected.
c One of 3 patients with MDR-TB demonstrated the D-series resolvin(s), trehalose-6-mycolate and PI metabolites in plasma.
d One of the 17 smear-negative household contacts demonstrated both trehalose-6-mycolate and the PI metabolites in plasma, but these metabolites were
undetectable the other household contacts.
The D-series resolvin metabolite(s) was detected in plasma of 2 other household contacts.
doi:10.1371/journal.pone.0108854.t002
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significant metabolites to correctly classify the TB patients and
household contact controls in this cohort.
Despite the limited coverage, considerable information has been
gained from metabolomic analyses. For example, Weiner et al,
using low-resolution MS and gas chromatography MS (GC-MS)
methods, explored the metabolome of 428 distinct small molecules
in a cross-sectional study in healthy controls, asymptomatic
patients with latent TB, and patients with active TB disease
[24]. A total of 20 metabolites differentiated subjects with TB
disease (n=44) compared to those with latent TB (n=46) and
healthy individuals (n=46) combined. In subjects with TB disease,
these included altered abundance of several amino acids, and
increased N-acetylneuraminate, pyroglutamine (glutamate metab-
olism), inosine, and mannose [24].
Our data show for the first time m/z matches for two Mtb cell
wall components in the plasma of patients with TB disease, the
verified glycolipid trehalose-6-mycolate (a component of the
mycolic acid layer of the cell wall) and PI. PI is a common
component of cell wall membranes in both bacteria and humans
and could be derived from various sources in these human
subjects. However, these metabolites were detected concomitantly
in 14 of 17 of the TB disease subjects at this similar early time
point after clinical diagnosis of TB disease (Table 2). Mannose,
which was upregulated in TB disease in the Weiner report [24], is
a critical component of the Mtb cell wall glycan lipoarabinoman-
nan (LAM) [47,48,54,55] and is required for mycobacterial growth
[56]. Relevant to our findings, in the Mtb cell wall LAM is
anchored to both the mycolic acid layer and the cell membrane by
PI [47,48]. Therefore, it is possible that the increased mannose
identified by Weiner et al. [24] was derived from cell walls of the
infecting Mtb, consistent with our observations of the elevated
metabolites matching to PI and trehalose-6-mycolate.
Previous metabolomic studies noted a variety of amino acid
alterations that distinguished TB disease from controls [21,23,24].
We identified glutamate to be elevated in TB disease as the only
discriminating amino acid (Table S2 in File S1), consistent with
the upregulation of serum glutamate in TB disease noted by Zhou
et al. [21] and, metabolically, with the decreased glutamine and
elevated pyroglutamine noted by Weiner et al. [24]. Glutamate is
a major amino acid utilized by Mtb during the growth phase [57]
and this amino acid is a critical constituent for components of the
Mtb cell wall [15,58]. After granuloma formation in the host, Mtb
shifts from a predominantly aerobic energy metabolism to
anaerobic metabolism in the oxygen-limiting environment of the
granuloma. Previous biochemical and targeted metabolomic
studies have shown that varient tricarboxylic acid cycle pathways
are employed by Mtb under hypoxic conditions, including a half-
cycle to generate succinate from GABA that utilizes increased
glutamate availability as a substrate [14,17]. The C
5 branched
dibasic acid metabolic pathway is also utilized by Mtb to provide
alternative carbon and nitrogen sources for energy, including
glutamate [15,59]. The upregulated glutamate in the differentiat-
ing plasma profile of this cohort of TB disease subjects may thus be
a result of increased Mtb glutamate synthesis and represent a
potential host-pathogen metabolic interaction.
This is the first study to identify an increase in specific resolvins
in individuals with TB. Resolvins are lipid mediators derived from
endogenous omega-3 fatty acids (DHA) from a genus of anti-
inflammatory and specialized pro-resolving lipid mediators (SPM):
resolvins, protectins, maresins, and lipoxins [32,34,35,60]. In-
creased local production of D-series resolvins occurs during
infection at sites of macrophage recruitment, particularly when
macrophages are clearing apoptotic polymorphonuclear neutro-
phils (PMN) [31,34,61,62]. D-series resolvins act as autocrine
signals and facilitate phagocytosis and microbial killing by a
variety of mechanisms. Apoptotic PMN themselves produce SPM
and their uptake by macrophages (efferocytosis) during bacterial
infection also stimulates macrophage synthesis of D-series
resolvins, which, in turn, induce local anti-inflammatory effects
and enhance microbial clearance [31,34,60,61,63]. RvD1 limits
neutrophil-mediated tissue injury, acute inflammatory responses
and trans-endothelial migration in inflammatory lung diseases in
mice [63]. In a murine microbial sepsis model, RvD2 significantly
dampened the local and systemic bacterial burden by preventing
excessive leukocyte infiltration and enhancing clearance of
microbes [62].
The upregulation of resolvins RvD1 and RvD2 in plasma of this
small cohort of recently diagnosed TB disease patients likely
reflects a host response to infection and tissue damage/inflamma-
tion (compared to the lack of this response in the apparently
uninfected household contacts). To our knowledge, no publica-
tions have identified upregulation of any resolvin species in the
blood of patients with non-TB lung diseases, although resolvin E1
was identified in the sputum of adult cystic fibrosis patients [64].
Our findings likely reflect a non-specific host homeostatic
response, however, given that the circulating resolvins RvD1
and RvD2 are detectable in serum, plasma and lymphoid organs
of healthy individuals and can be upregulated in blood, for
example, by oral fish oil [32,65]. Although the role of resolvins in
Mtb infection is currently little understood, the results shown in
Table 2 suggest the possibility of a common pathophysiologic
pathway in this cohort of TB disease subjects involving events that
result in local generation of D-series resolvins in the lung
granuloma that are detectable in plasma, concomitant with the
presence of specific Mtb cell wall-related metabolites.
Limitations of this study include the cross-sectional nature, with
single plasma samples obtained within the first week of drug
therapy, the relatively small sample size and the few patients
studied with MDR-TB. In addition, while the household contacts
did not have active TB disease, no studies were carried out to
assess whether they had latent TB infection. Further metabolomic
studies are needed among patients with documented latent TB
infection to detect potential biomarkers for transition to active
disease. Another limitation of this pilot study is that we cannot
explicitly determine relationships between identified metabolites
and anti-TB therapy or TB progression. Also, our FDR controlling
procedures exert less stringent control over false discovery
compared to family wise error rate procedures (such as the
Bonferroni correction); thus, we have consequently avoided over-
interpretation of these data. As we had no a priori basis for a
power calculation, this report should be viewed as hypothesis-
generating and needs to be confirmed in a larger study. We did not
obtain absolute identity of most of the discriminating metabolites
by tandem MS/MS studies using authentic standards. Metabolites
in plasma are an indirect measure of Mtb metabolism and local
tissue response to infection; thus, metabolomics data from patient
sputum or the Mtb organism itself would be of interest.
In summary, these pilot data show that adults with active TB
disease can be differentiated from persons without active TB
disease by high-resolution metabolic profiling of plasma. We were
able to identify multiple metabolites relevant to Mtb disease
(including Mtb cell wall components) and its unique metabolism,
as well as D-series resolvins that may reflect a general response to
TB disease in humans. Prospective and confirmatory studies are
needed to gain pathophysiologic insight before and after initiation
of conventional anti-TB drug therapy to better understand the
significance of these novel findings. Of interest would be studies to
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opment of TB disease in individuals with latent TB, whether
metabolite profiling can identify subjects with drug-susceptible
versus MDR-TB, and the utility of these approaches and specific
metabolomic signatures to predict responses to new anti-TB
therapies including vaccines and newer drug combinations.
Supporting Information
Figure S1 Principal component analysis (PCA; panels A,
B and C) showed a similar metabolite separation
pattern between TB disease subjects and household
contacts as seen with two-way hierarchical cluster
analysis (HCA) (Figure 1A). The model was evaluated using
the R2 and Q2 estimates (panel D). The model using the first two
principal components suggests good predictive ability (PC1:
R2=0.44, Q2=0.40; PC2: R2=0.7, Q2=0.64; PC3:
R2=0.74, Q2=0.60). Green squares=TB disease subjects (TB);
Red squares=household contacts (HC).
(TIF)
Figure S2 MS/MS fragmentation spectra show positive
identification of trehalose 6-mycolate. Authentic standard
trehalose-6-mycolate was purified from Mtb at the Colorado State
University Mycobacteria Research Laboratory, Fort Collins, CO.
MS/MS spectra for m/z 801.5727 at collision energy of 35% for
1 uM trehalose 6-mycolate (A) and plasma (B). Presence of
fragments 184.0736 and 86.0970 in both the reference standard
and plasma sample at the same retention time indicate the match
to the [M-H2O+H] adduct for trehalose 6-mycolate is correct.
(TIF)
Text S1 This file contains all 61 significant m/z,
retention times, minimum and maximum m/z, number
of peaks, median coefficient of variation, and an
internal scoring system (QRscore) with intensities for
all samples included in this study.
(TXT)
File S1 Supporting Tables.
(DOCX)
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